Interview with Sirirurg Songsivilai, Executive Director, NANOTEC
As one of the leading figures of nanotechnology in Thailand, would you introduce yourself to our readers? I am a researcher by training. I hold a medicine degree and PhD…
Address: CRC Tower, 23rd Floor, All Seasons Place 87/2 Wireless Road, Lumpini, Pathumwan Bangkok 10330
,Thailand
Tel: +66 (0) 2264 9999
Web: http://www.sanofipasteurthailand.com/sanofi-pasteur2/
Immunization saves more than 3 million lives every year in all age groups from diphtheria, tetanus, pertussis and measles – but more than 3 million people still die due to lack of access to vaccines.
Our vision is a world in which no one suffers or dies from a vaccine-preventable disease.
To achieve our vision, we rely on cooperation, innovation and education. Informing the public about the burden of disease and the true value of vaccines will help maintain and develop greater immunization coverage, and as a result, save lives.
Sanafi-Aventis has been developing in Thailand since 1978 in both the private sector, with Aventis Pasteur Thailand since 2000, and the public sector, through a joint venture with GPO-MBP implemented in 1998.
Sanofi Pasteur has the broadest available range of vaccines, protecting against 20 infectious diseases:
World’s largest producer of seasonal influenza vaccines: more than 200 million doses provided in 2011
World’s leading provider of inactivated poliomyelitis vaccine
Broadest range of modern pediatric combination vaccines for children throughout the world
World’s main provider of meningococcal vaccines with an unfaltering commitment to provide meningococcal vaccine for outbreaks control in West Africa
Largest portfolio of vaccines for travelers and people living in tropical areas: typhoid, rabies, yellow fever, Japanese encephalitis, meningococcal meningitis, cholera, hepatitis A, hepatitis B
Our vaccines protect against 20 infectious diseases.
Bacterial diseases:
Cholera
Diphtheria
Haemophilus influenzae type b Infections
Meningococcal Infections
Pertussis
Pneumococcal Infections
Tetanus
Tuberculosis
Typhoid Fever
Viral diseases:
Hepatitis A
Hepatitis B
Influenza
Japanese Encephalitis
Measles
Mumps
Poliomyelitis
Rabies
Rubella
Varicella
Yellow Fever
and smallpox, eradicated in 1980 (vaccine produced as a measure in response to the threat of bioterrorism)
As one of the leading figures of nanotechnology in Thailand, would you introduce yourself to our readers? I am a researcher by training. I hold a medicine degree and PhD…
Practical Law Company nominated TILLEKE & GIBBINS the “Leading” Life Sciences firm in Thailand The nomination was based on firm and lawyer track records – could you describe what makes…
Novo Nordisk is one of the very few pharmaceutical multinationals that have a strong focus on one therapeutic area. Although the company has a presence in other disease areas, diabetes…
Dr Ammelburg, you have been working for Roche for more than 25 years now, time essentially spent between your home country Germany and Thailand. After more than 10 years spent…
You are General Manager for Thailand and Vietnam; two markets that certainly interest companies but at a very different stage of development. What are according to you the main differences…
Mr. Ammelburg of Roche described Thailand as a very difficult and different market and according to PReMA figures there was only 2 percent growth last year. Nevertheless, global projections rank…
TPMA is the main association bringing together the local manufacturers in Thailand. What do you consider to have been the main milestones and achievements since your inception? We haven’t reached…
PReMa was established in 2004 after a period of transformation to represent the growing role of its members, research-based companies. To begin with, could you explain us the main milestones…
Thailand might already have become a medical tourism destination but the country still needs to sort out serious issues on its local market as the country healthcare system is largely…
See our Cookie Privacy Policy Here
